苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪(Amlodipine Besylate/Azilsartan/Hydrochlorothiazide) - 药物靶点：AT1R x CYP1A2 x NCC x VDCCs_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Amlodipine/azilsartan/hydrochlorothiazide、Amlodipine/hydrochlorothiazide/azilsartan、Azilsartan/amlodipine/hydrochlorothiazide

+ [5]

靶点

AT1R x CYP1A2 x NCC x VDCCs

作用方式

拮抗剂、抑制剂、阻滞剂

作用机制

AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、CYP1A2抑制剂(细胞色素P-450 CYP1A2抑制剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

+ [1]

治疗领域

心血管疾病

在研适应症-

非在研适应症

原发性高血压

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构-

非在研机构

Takeda Pharmaceutical Co., Ltd.

权益机构-

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H31ClN2O8S

InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N

CAS号111470-99-6

查看全部结构式(3)

关联

3

项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的临床试验

JPRN-jRCT2080222725

/ Unknown status临床1期

A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose Administration of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects

开始日期2015-01-21

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT02348658

/ Completed临床1期

A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects

This is a phase 1, randomized, open-label, crossover study to evaluate the food-effect of single oral dose of TAK-536TCH final formulation tablet in healthy adult male participants.

开始日期2015-01-01

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT02277691

/ Completed临床3期

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

开始日期2014-11-07

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

100 项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的临床结果

登录后查看更多信息

100 项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的转化医学

登录后查看更多信息

100 项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的专利（医药）

登录后查看更多信息

1

项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的文献（医药）

2019-09-12·International journal of molecular sciences

Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018

Review

作者: Ni, Bingwei ; Cui, Qiuji ; Li, Tingting ; Jiang, Sida ; Liu, Qinan ; Zhao, Hongping

Cardiovascular drug research and development (R&D) has been in active state and continuously attracts attention from the pharmaceutical industry. However, only one individual drug can eventually reach the market from about the 10,000 compounds tested. It would be useful to learn from these failures when developing better strategies for the future. Discontinued drugs were identified from a search performed by Thomson Reuters Integrity. Additional information was sought through PubMed, ClinicalTrials.gov, and pharmaceutical companies search. Twelve compounds discontinued for cardiovascular disease treatment after reaching Phase I-III clinical trials from 2016 to 2018 are detailed in this manuscript, and the reasons for these failures are reported. Of these, six candidates (MDCO-216, TRV027, ubenimex, sodium nitrite, losmapimod, and bococizumab) were dropped for lack of clinical efficacy, the other six for strategic or unspecified reasons. In total, three candidates were discontinued in Phase I trials, six in Phase II, and three in Phase III. It was reported that the success rate of drug R&D utilizing selection biomarkers is higher. Four candidate developments (OPC-108459, ONO-4232, GSK-2798745, and TAK-536TCH) were run without biomarkers, which could be used as surrogate endpoints in the 12 cardiovascular drugs discontinued from 2016 to 2018. This review will be useful for those involved in the field of drug discovery and development, and for those interested in the treatment of cardiovascular disease.

100 项与苯磺酸氨氯地平/阿齐沙坦/氢氯噻嗪相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	日本	Takeda Pharmaceutical Co., Ltd.	2014-11-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02277691 (CTgov)	临床3期	原发性高血压	341	TAK-536CCB tablet+HCTZ 12.5 mg tablet+TAK-536TCH tablet	(夢淵壓夢積鏇範觸鬱鬱) = 艱鹹積網遞餘餘願壓願淵窪夢鹽製網餘鏇範範 (壓蓋鑰積願願壓繭膚餘, 積願繭膚願範範獵窪繭 ~ 選鏇蓋積鹹獵積齋艱積) 更多	-	2017-06-26
NCT02348658 (CTgov)	临床1期	高血压	12	TAK-536TCH (TAK-536TCH Fasted)	憲齋積壓簾醖鬱顧蓋憲(蓋簾膚遞衊網鑰襯糧蓋) = 窪願夢衊鑰鹹選淵窪夢網遞衊衊鹹繭廠獵願觸 (觸襯顧簾鏇鏇壓簾選鏇, 廠鑰觸鹽蓋遞衊觸膚糧 ~ 獵廠醖簾憲構糧願膚窪) 更多	-	2016-04-26
NCT02348658 (CTgov)	临床1期	高血压	12	TAK-536TCH (TAK-536TCH Fed)	憲齋積壓簾醖鬱顧蓋憲(蓋簾膚遞衊網鑰襯糧蓋) = 壓鹹遞網繭齋構鹹鑰壓網遞衊衊鹹繭廠獵願觸 (觸襯顧簾鏇鏇壓簾選鏇, 鏇構構網窪遞願膚夢蓋 ~ 憲簾積顧壓選構製衊艱) 更多	-	2016-04-26